The GAstric Precancerous Conditions Study

Gastric Cancer Clinical Trial

— GAPS  

Official title:

The GAstric Precancerous Conditions Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04191551
• Other study ID #: 45077
• Status: Recruiting
• Start date: July 30, 2018
• Est. completion date: June 30, 2026

Study information

• Verified date: April 2023
• Source: Stanford University
• Contact: Robert J Huang, MD
• Phone: 650-725-0634
• Email: rjhuang[@]stanford.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gastric cancer afflicts 27,000 Americans annually and carries a dismal prognosis. One reason for poor outcomes is late diagnosis, as the majority of gastric cancers in the United States are diagnosed at a relatively advanced stage where curative resection is unlikely. Gastric intestinal metaplasia (GIM) is a precancerous change of the stomach which increases risk for subsequent gastric cancer multiple-fold.

The Gastric Precancerous Conditions Study (GAPS) is an observational study with two over-arching objectives: 1) improve the non-invasive identification of patients with GIM, and 2) develop biological markers to predict the subset of GIM which will progress onto gastric cancer.

To achieve Aim 1, a case-control study (N=300 pairs) matching cases of GIM with age-/gender-matched controls will be recruited form the population of subjects undergoing clinically-indicated endoscopy. Determination of gastric pathology will be made by two, independent gastrointestinal pathologists. At time of endoscopy, a detailed clinical questionnaire is administered by face-to-face interview. Saliva and blood is collected prior to endoscopy. At time of endoscopy, protocoled clinical biopsies (per Revised Sydney Protocol) as well as additional research specimens are collected. Scoring of GIM will be performed based on the Operative Link for GIM scoring system.

To achieve Aim 2, patients with histologically-confirmed GIM (N=300) will be followed longitudinally. Biennial endoscopic surveillance will be performed, with repeat biopsies, specimen collection, and histologic scoring. Progression of GIM will be defined as upstaging of GIM score, or development of either dysplasia or carcinoma on any biopsy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: June 30, 2026
• Est. primary completion date: June 30, 2024
• Gender: All
• Age group: 35 Years to 84 Years

Eligibility

Inclusion Criteria: Subjects between the ages of 35 and 84, who are undergoing outpatient endoscopy for the following indications are eligible: abdominal pain, dyspepsia, iron deficiency anemia, Helicobacter assessment, surveillance of suspected or known intestinal metaplasia, evaluation for family history of gastric cancer

Exclusion Criteria:

• Cannot give consent

• Have history of gastric surgery

• Have history of solid tumor or bone marrow transplant

• Platelet Count < 70 or international normalized ratio > 1.5

Related Conditions & MeSH terms

• Atrophic Gastritis
• Gastric Cancer
• Gastritis
• Gastritis, Atrophic
• Helicobacter Pylori Infection
• Intestinal Metaplasia of Gastric Mucosa
• Metaplasia
• Precancerous Conditions

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression of intestinal metaplasia	Progression will be assessed using the Operative Link for Gastric Intestinal Metaplasia (Reference 1). This score reflects both the histologic severity as well as anatomic location of intestinal metaplasia. Scores range from 0 (no metaplasia) to 4 (severe metaplasia). It is believed that higher scores portend a higher risk for progression to cancer.	24 months following enrollment